Recombinant human endostatin adenovirus (Chengdu Shi Endor Biological Engineering Technology)

重组人内皮抑素腺病毒（成都恩多施生物工程）

Report date: 2023/10/26 17:10:54

Base Information

Drug NameRecombinant human endostatin adenovirus (Chengdu Shi Endor Biological Engineering Technology)
Drug Alias NameRecombinant human endostatin adenovirus in重组人内皮抑素腺病毒zh重组人内皮抑素腺病毒 - Chengdu Shi Endor Biological Engineering TechnologyEDS-01
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionAngiogenesis inhibitorsCOL18A1 gene transference
TargetsEndostatin
Therapy Area/IndicationsNasopharyngeal CarcinomaSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Enduoshi Biological Engineering Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Enduoshi Biological Engineering Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsNasopharyngeal CarcinomaSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A